AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8673651 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived health
Number of subjects: 1051
Study 8673651 — intervention group
Group type: EXPERIMENTAL
Intervention: Being Catholic
Number of subjects: 1051
Study 1761810 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.6 U/kg/week sc 5‐6 times/week
Number of subjects: 16
Study 1761810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oxandrolone 0.07 mg/kg po
Number of subjects: 16
Study 1761810 — intervention group
Group type: COMPARATOR
Intervention: Both GH and oxandrolone
Number of subjects: 16
Study 1761810 — intervention group
Group type: COMPARATOR
Intervention: GH or oxandrolone
Number of subjects: 16
Study 6366806 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg salbutamol 3-times daily
Number of subjects: 48
Study 6366806 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms clenbuterol twice daily
Number of subjects: 48
Study 6366806 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms clenbuterol twice daily
Number of subjects: 48
Study 31810217 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle intervention
Number of subjects: 629
Study 31810217 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 629
Study 30358674 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Family Room (SFR)
Number of subjects: 115
Study 30358674 — intervention group
Group type: COMPARATOR
Intervention: Open Bay (OB)
Number of subjects: 115
Study 27364038 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalaki rasayana
Number of subjects: 0
Study 27364038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25098981 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (vermisole 150 mg, once daily for the first 3 days of 3 weeks in a month for 3 months with a gap of 1 week)
Number of subjects: 30
Study 25098981 — intervention group
Group type: COMPARATOR
Intervention: Control group (no levamisole)
Number of subjects: 30
Study 22212648 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha plus ribavirin therapy
Number of subjects: 526
Study 20587064 — intervention group
Group type: EXPERIMENTAL
Intervention: De Palma percutaneous pinning
Number of subjects: 100
Study 20587064 — intervention group
Group type: COMPARATOR
Intervention: Bridging external fixation
Number of subjects: 100
Study 20587064 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 17414740 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (200-800 mg/day)
Number of subjects: 377
Study 17414740 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 377
Study 17215640 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training group
Number of subjects: 131
Study 17215640 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic walking group
Number of subjects: 131
Study 17215640 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise group
Number of subjects: 131
Study 17215640 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising control group
Number of subjects: 131
Study 15498373 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion (acu‐moxi) alone
Number of subjects: 480
Study 15498373 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion (acu‐moxi) in combination with prednisone, Vitamin B1, vitamin B12, and dibazole
Number of subjects: 480
Study 15498373 — intervention group
Group type: COMPARATOR
Intervention: Control group (prednisone, vitamin B1, vitamin B12, and dibazole)
Number of subjects: 480
Study 10694777 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 21
Study 10694777 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (2 g tea solids in 300 ml water)
Number of subjects: 21
Study 10694777 — intervention group
Group type: COMPARATOR
Intervention: Black tea with milk
Number of subjects: 21
Study 10694777 — intervention group
Group type: COMPARATOR
Intervention: Green tea with milk
Number of subjects: 21
Study 10694777 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 21
Study 9351400 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol (RRR-AT)
Number of subjects: 79
Study 9351400 — intervention group
Group type: EXPERIMENTAL
Intervention: all-racemic alpha-tocopherol (all-rac-AT)
Number of subjects: 79
Study 1389935 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual verapamil 40 mg (Securon)
Number of subjects: 6
Study 1389935 — intervention group
Group type: COMPARATOR
Intervention: Oral verapamil 40 mg (Securon)
Number of subjects: 6
Study 3934544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 6
Study 3934544 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 6
Study 31050143 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 318
Study 31050143 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 3.0 mg
Number of subjects: 318
Study 31050143 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 4.5 mg
Number of subjects: 318
Study 31050143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 29211866 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mmol/kg/d potassium bicarbonate (KHCO3)
Number of subjects: 233
Study 29211866 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mmol/kg/d potassium bicarbonate (KHCO3)
Number of subjects: 233
Study 29211866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 26359449 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0
Study 26359449 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 23057502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 120
Study 23057502 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 120
Study 23057502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 22212494 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% diltiazem ointment
Number of subjects: 93
Study 22212494 — intervention group
Group type: COMPARATOR
Intervention: 0.2% glyceryl trinitrate
Number of subjects: 93
Study 22212494 — intervention group
Group type: COMPARATOR
Intervention: 10% lidocaine
Number of subjects: 93
Study 20299984 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 74
Study 20299984 — intervention group
Group type: COMPARATOR
Intervention: Control (no N-acetylcysteine)
Number of subjects: 74
Study 17583595 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg kg‐1 (Group I, n = 40)
Number of subjects: 120
Study 17583595 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium 30 mg kg‐1 (Group II, n = 40)
Number of subjects: 120
Study 17583595 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group III, n = 40)
Number of subjects: 120
Study 15604003 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary wheelchair ergometer
Number of subjects: 30
Study 15604003 — intervention group
Group type: COMPARATOR
Intervention: Motor-driven treadmill
Number of subjects: 30
Study 15604003 — intervention group
Group type: COMPARATOR
Intervention: Circular wheelchair track
Number of subjects: 30
Study 12197844 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg twice daily for 8 weeks)
Number of subjects: 28
Study 12197844 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsules for 8 weeks)
Number of subjects: 28
Study 12197844 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 28
Study 9451563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) sampling from the center and 12:00 region
Number of subjects: 74
Study 9451563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) sampling from 3 sequential regions
Number of subjects: 74
Study 9451563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) sampling from 4 sequential regions
Number of subjects: 74
Study 9451563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) sampling from the center region
Number of subjects: 74
Study 9451563 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration (FNA) sampling including the 12:00 region
Number of subjects: 74
Study 9451563 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of nodules characterized as malignant (M) or suspicious/neoplastic (S/N)
Number of subjects: 74
Study 9451563 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up of benign (B) nodules
Number of subjects: 74
Study 7892843 — intervention group
Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring (monitored group)
Number of subjects: 218
Study 7892843 — intervention group
Group type: COMPARATOR
Intervention: Routine high-risk prenatal care alone (unmonitored group)
Number of subjects: 218
Study 2496434 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine smoke-free cigarettes
Number of subjects: 40
Study 2496434 — intervention group
Group type: COMPARATOR
Intervention: Placebo smoke-free cigarettes
Number of subjects: 40
Study 1015009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cendehill vaccination
Number of subjects: 159
Study 1015009 — intervention group
Group type: EXPERIMENTAL
Intervention: RA 27/3 vaccination
Number of subjects: 159
Study 1015009 — intervention group
Group type: COMPARATOR
Intervention: Control group (not protected by natural immunity or vaccination)
Number of subjects: 159
Study 1015009 — intervention group
Group type: COMPARATOR
Intervention: Control group (protected by natural immunity)
Number of subjects: 159
Study 30773863 — intervention group
Group type: EXPERIMENTAL
Intervention: IHTAN + acupoint injection
Number of subjects: 88
Study 30773863 — intervention group
Group type: COMPARATOR
Intervention: Warm needle moxibustion + acupoint injection
Number of subjects: 88
Study 30773863 — intervention group
Group type: COMPARATOR
Intervention: Acupoint injection
Number of subjects: 88
Study 30238433 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat 2 mg
Number of subjects: 20
Study 30238433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27262302 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 200
Study 27262302 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 200
Study 24189477 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT with defibrillator (CRT-D)
Number of subjects: 259
Study 24189477 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT without defibrillator back-up
Number of subjects: 259
Study 22805294 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% w/v calcium phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) paste
Number of subjects: 296
Study 22805294 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 296
Study 20808092 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-delivered problem adaptation therapy (PATH)
Number of subjects: 30
Study 20808092 — intervention group
Group type: COMPARATOR
Intervention: Home-delivered supportive therapy (ST)
Number of subjects: 30
Study 17209889 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced education consisting of weekly e-mailed case scenarios and clinical questions on 2 of the 4 urology topics.
Number of subjects: 95
Study 17209889 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail, but implied to be students who did not receive spaced education).
Number of subjects: 95
Study 16420078 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 230
Study 16420078 — intervention group
Group type: COMPARATOR
Intervention: Reboxetine
Number of subjects: 230
Study 12934761 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Mousse (20% acetate vitamin E) applied twice daily for 3 weeks
Number of subjects: 40
Study 12934761 — intervention group
Group type: COMPARATOR
Intervention: Control group (contralateral leg untreated)
Number of subjects: 40
Study 10367574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrastromal corneal ring segment (ICRS) procedure
Number of subjects: 94
Study 8916997 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind vaginal swab technique
Number of subjects: 88
Study 8916997 — intervention group
Group type: COMPARATOR
Intervention: Speculum examination
Number of subjects: 88
Study 8916997 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 88
Study 1913767 — intervention group
Group type: EXPERIMENTAL
Intervention: Least thorough rinsing procedure (5 ml x 2 s once)
Number of subjects: 8
Study 1913767 — intervention group
Group type: COMPARATOR
Intervention: Most thorough rinsing procedure (20 ml x 10 s twice)
Number of subjects: 8
Study 1913767 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing rinse volume, rinse duration, and rinse frequency
Number of subjects: 8
Study 6130066 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone (average 16.5 mg/day)
Number of subjects: 100
Study 6130066 — intervention group
Group type: COMPARATOR
Intervention: diazepam (15 mg/day)
Number of subjects: 100
Study 30880505 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 mg of MYO + 150 mg of DCI twice daily
Number of subjects: 60
Study 30880505 — intervention group
Group type: COMPARATOR
Intervention: 550 mg of MYO + 13.8 mg of DCI twice daily
Number of subjects: 60
Study 30043130 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 81
Study 30043130 — intervention group
Group type: COMPARATOR
Intervention: Nilotinib
Number of subjects: 81
Study 26850310 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly nutrition lessons focused on benefits of fruit and vegetable consumption
Number of subjects: 54
Study 26850310 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly nutrition lessons and provision of one serving of fruits and two servings of vegetables per day for 10 weeks
Number of subjects: 54
Study 26850310 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 54
Study 24642201 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond consumption (0, 1.5, or 3 servings/day for 18 days)
Number of subjects: 34
Study 24642201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio consumption (0, 1.5, or 3 servings/day for 18 days)
Number of subjects: 34
Study 21819279 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment for 10 weeks
Number of subjects: 34
Study 20652463 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based personalized genetic feedback
Number of subjects: 200
Study 20652463 — intervention group
Group type: COMPARATOR
Intervention: Attention-control feedback
Number of subjects: 200
Study 17435110 — intervention group
Group type: EXPERIMENTAL
Intervention: standard forecast + UV
Number of subjects: 557
Study 17435110 — intervention group
Group type: EXPERIMENTAL
Intervention: standard forecast + UV + sun-protection messages
Number of subjects: 557
Study 17435110 — intervention group
Group type: COMPARATOR
Intervention: standard forecast (no UV)
Number of subjects: 557
Study 15755866 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (850 mg/d)
Number of subjects: 235
Study 15755866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 12409108 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT specialist CT (n=60)
Number of subjects: 110
Study 12409108 — intervention group
Group type: COMPARATOR
Intervention: Control CT (n=50)
Number of subjects: 110
Study 9040677 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAS surgical patients
Number of subjects: 277
Study 9040677 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAS-eligible patients not enrolled and ACAS surgeons
Number of subjects: 277
Study 9040677 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAS-eligible patients not enrolled and non-ACAS surgeons
Number of subjects: 277
Study 9040677 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAS-ineligible patients and ACAS surgeons
Number of subjects: 277
Study 9040677 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAS-ineligible patients and non-ACAS surgeons
Number of subjects: 277
Study 7893868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (120 mg/[kg.d])
Number of subjects: 379
Study 7893868 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (160 mg/[kg.d])
Number of subjects: 379
Study 2447403 — intervention group
Group type: EXPERIMENTAL
Intervention: epanolol, 200 mg b.i.d.
Number of subjects: 30
Study 2447403 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol, 10 mg b.i.d.
Number of subjects: 30
Study 2447403 — intervention group
Group type: EXPERIMENTAL
Intervention: epanolol, 400 mg q.d.
Number of subjects: 30
Study 2447403 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol, 10 mg b.i.d. and epanolol, 200 mg b.i.d.
Number of subjects: 30
Study 31219519 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal controls in randomized clinical trials
Number of subjects: 79
Study 31219519 — intervention group
Group type: COMPARATOR
Intervention: Suboptimal controls for genitourinary tumors
Number of subjects: 79
Study 31219519 — intervention group
Group type: COMPARATOR
Intervention: Suboptimal controls for lung/head and neck tumors
Number of subjects: 79
Study 29608967 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in older patients (65 years and older)
Number of subjects: 1006
Study 29608967 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy in younger patients (younger than 65 years)
Number of subjects: 1006
Study 29608967 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (65 years and older)
Number of subjects: 1006
Study 29608967 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 1006
Study 26520004 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 24
Study 26520004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24121497 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard NHS cardiac rehabilitation programme
Number of subjects: 24
Study 22561596 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) 0.2 mg orally
Number of subjects: 30
Study 22561596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19508877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic visual cues (scene structure, horizon)
Number of subjects: 0
Study 19508877 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrinsic visual cues (support structures)
Number of subjects: 0
Study 17991531 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day standard bowel preparation (group 1)
Number of subjects: 62
Study 17991531 — intervention group
Group type: COMPARATOR
Intervention: Soft diet with no oral intake 8 hours before surgery (group 2)
Number of subjects: 62
Study 15356967 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 114
Study 15356967 — intervention group
Group type: COMPARATOR
Intervention: Calcium Carbonate (CC)
Number of subjects: 114
Study 12006190 — intervention group
Group type: EXPERIMENTAL
Intervention: 532 nm, 2 ms pulse-duration Nd:YAG laser treatment for upper lip wrinkles
Number of subjects: 0
Study 12006190 — intervention group
Group type: EXPERIMENTAL
Intervention: 532 nm, 2 ms pulse-duration Nd:YAG laser treatment for facial acne scarring
Number of subjects: 0
Study 12006190 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated side) for upper lip wrinkles and facial acne scarring
Number of subjects: 0
Study 9893933 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 1 (chewable tablets containing 76 mg Na2FPO3 and 1250 mg calcium carbonate)
Number of subjects: 38
Study 9893933 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 2 (effervescent tablets containing 76 mg Na2FPO3 and 1250 mg calcium carbonate)
Number of subjects: 38
Study 9893933 — intervention group
Group type: COMPARATOR
Intervention: Ref1 (tablets containing 76 mg Na2FPO3)
Number of subjects: 38
Study 9893933 — intervention group
Group type: COMPARATOR
Intervention: Ref2 (effervescent tablets containing 76 mg Na2FPO3 and 3240 mg calcium lactogluconate/carbonate)
Number of subjects: 38
Study 8064320 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (anti-cholinesterase)
Number of subjects: 12
Study 8064320 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine (anticholinergic)
Number of subjects: 12
Study 8064320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8064320 — intervention group
Group type: COMPARATOR
Intervention: Untreated Alzheimer patients
Number of subjects: 12
Study 2840815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 2.5 mg
Number of subjects: 55
Study 2840815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 5.0 mg
Number of subjects: 55
Study 2840815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg
Number of subjects: 55
Study 2840815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (various doses)
Number of subjects: 55
Study 2840815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 55
Study 8018302 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatments to reduce hypertension and hyperlipidaemia
Number of subjects: 0
Study 8018302 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer models for estimating long term benefits of risk factor modification
Number of subjects: 0
Study 368370 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C prophylaxis, 2.0 g/day
Number of subjects: 674
Study 368370 — intervention group
Group type: COMPARATOR
Intervention: Placebo prophylaxis
Number of subjects: 674
Study 368370 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C prophylaxis
Number of subjects: 674
Study 31794152 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate hydrate (ZAH; 50 mg/day)
Number of subjects: 91
Study 31794152 — intervention group
Group type: COMPARATOR
Intervention: Polaprezinc (PPZ; 34 mg/day)
Number of subjects: 91
Study 30500960 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol for skin antisepsis
Number of subjects: 1038
Study 30500960 — intervention group
Group type: COMPARATOR
Intervention: Iodine-alcohol for skin antisepsis
Number of subjects: 1038